At the University of Texas at El Paso, researchers studying more than 142,000 patients have uncovered something unexpected: the same weight-loss drugs reshaping bodies may also be reshaping how the brain responds to addiction.
A new study led by UTEP School of Pharmacy researchers Tadesse Abegaz and Gabriel Frietze, published in Frontiers in Psychiatry, found that patients taking GLP-1 medications like Ozempic showed significantly lower rates of developing alcohol, opioid, nicotine, and cocaine use disorders compared to similar patients who were not on these drugs. Among the roughly 20,000 patients prescribed GLP-1s, the protective associations were striking: 74% lower odds of alcohol use disorder, 69% lower odds of opioid use disorder, 68% lower odds of nicotine use disorder, and 75% lower odds of cocaine use disorder.
The discovery matters because it hints at something larger about how these medications work. GLP-1s were originally developed to treat obesity and Type 2 diabetes by regulating appetite and blood sugar. But emerging evidence suggests they may do far more—influencing dopamine signaling and other neural pathways that drive not just hunger, but craving itself. "These medications appear to affect brain pathways involved in reward and craving, which could help explain the lower rates of substance use disorders observed in our study," Abegaz explained.
The research comes from data provided by the National Institutes of Health's All of Us Research Program, which examined patients with Type 2 diabetes or obesity in a nested case-control study. Yet the researchers were careful to pump the brakes on premature hope. Frietze emphasized that the findings do not establish cause and effect—and crucially, that GLP-1s should not yet be prescribed for addiction treatment. "Because this was an observational study in a specific clinical population, randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction," he said.
What makes this work compelling is not what it claims, but what it leaves open. The team believes the results are promising enough to warrant further investigation. Abegaz outlined plans for prospective research that would follow individuals over time as they initiate GLP-1 therapy, tracking whether changes in substance use behaviors occur after treatment begins and whether those changes correlate with improvements in mental health and quality of life. The goal is eventually to determine whether GLP-1 medications could become part of future treatment strategies for substance use disorders.
For now, the study serves as a reminder of how interconnected our bodies truly are. A medication developed to help people lose weight has revealed something about the reward pathways that drive addiction—pathways that affect millions struggling with alcohol, opioids, nicotine, and cocaine. The discovery opens a door, inviting researchers to ask harder questions about what's happening in the brain when these drugs take effect. The answers could reshape not just weight management, but how we approach one of medicine's most persistent challenges.